1. Home
  2. ALLO vs TKNO Comparison

ALLO vs TKNO Comparison

Compare ALLO & TKNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$1.50

Market Cap

252.9M

Sector

Health Care

ML Signal

HOLD

Logo Alpha Teknova Inc.

TKNO

Alpha Teknova Inc.

HOLD

Current Price

$4.80

Market Cap

236.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALLO
TKNO
Founded
2017
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
252.9M
236.6M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
ALLO
TKNO
Price
$1.50
$4.80
Analyst Decision
Buy
Analyst Count
11
0
Target Price
$8.67
N/A
AVG Volume (30 Days)
2.4M
135.2K
Earning Date
11-06-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$39,801,000.00
Revenue This Year
N/A
$8.79
Revenue Next Year
$100.00
$10.52
P/E Ratio
N/A
N/A
Revenue Growth
N/A
9.50
52 Week Low
$0.86
$3.94
52 Week High
$3.78
$10.37

Technical Indicators

Market Signals
Indicator
ALLO
TKNO
Relative Strength Index (RSI) 61.26 51.98
Support Level $1.39 $4.53
Resistance Level $1.52 $4.87
Average True Range (ATR) 0.10 0.28
MACD 0.01 0.04
Stochastic Oscillator 87.50 91.55

Price Performance

Historical Comparison
ALLO
TKNO

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

About TKNO Alpha Teknova Inc.

Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.

Share on Social Networks: